[The use of vinpocetine in chronic disorders caused by cerebral hypoperfusion].
The clinical signs and symptoms of so-called "cerebrovascular insufficiency" or "cerebral vascular dysfunction" have the characteristics of those of chronic cerebral hypoperfusion. The clinical features of chronic cerebral hypoperfusion often show the symptoms of cognitive impairment and organic psychosyndromes. Cerebral hypoperfusion could be found in dementias of different origin (subcortical arteriosclerotic leucoencephalopathy [Binswanger], vascular dementia, Alzheimer's disease, etc.). Pathological changes caused by chronic cerebral hypoperfusion often confined only to the white matter (demyelisation, glial activation, damage of oligodendroglial cells, as well as scattered cell death). Each therapy has an influence on the biochemical and pathophysiological alterations caused by chronic cerebral hypoperfusion can be used with reason in these disorders. The mechanism of action of vinpocetine is interfering on many aspects with the biochemical and pathophysiological processes attributable to chronic cerebral hypoperfusion, independently of the original alteration responsible for hypoperfusion. This fact might give an explanation on the beneficial effect of vinpocetine on clinical signs and symptoms of chronic cerebrovascular insufficiency.
Pest Megyei Onkormányzat Flór Ferenc Kórháza, Kistarcsa, Neurológiai Osztály.
S
S
Horváth
D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003071:Cognition / Q000187:drug effects; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D005858:Germany; D006801:Humans; D002534:Hypoxia, Brain / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D007558:Italy; D007564:Japan; D008568:Memory / Q000187:drug effects; D008569:Memory Disorders / Q000188:drug therapy / Q000209:etiology; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018697:Nootropic Agents / Q000627:therapeutic use; D012720:Severity of Illness Index; D015222:Sodium Channels / Q000187:drug effects; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*; D014748:Vinca Alkaloids / Q000627:therapeutic use*
D002121:Calcium Channel Blockers; D018696:Neuroprotective Agents; D018697:Nootropic Agents; D015222:Sodium Channels; D014665:Vasodilator Agents; D014748:Vinca Alkaloids; C013983:vinpocetine